Principal Financial Group Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 216,660 shares of the life sciences company’s stock after selling 3,177 shares during the period. Principal Financial Group Inc. owned approximately 0.15% of Illumina worth $64,983,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Caxton Associates LP purchased a new position in Illumina in the 4th quarter valued at approximately $239,000. Achmea Investment Management B.V. boosted its position in Illumina by 24.6% in the 4th quarter. Achmea Investment Management B.V. now owns 8,937 shares of the life sciences company’s stock valued at $2,680,000 after buying an additional 1,766 shares during the period. PRW Wealth Management LLC purchased a new position in Illumina in the 4th quarter valued at approximately $53,000. Stamos Capital Partners L.P. purchased a new position in Illumina in the 4th quarter valued at approximately $1,055,000. Finally, LMR Partners LLP purchased a new position in Illumina in the 4th quarter valued at approximately $1,657,000. Institutional investors and hedge funds own 89.18% of the company’s stock.
Several equities research analysts have recently issued reports on ILMN shares. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $340.00 to $370.00 in a research report on Thursday, January 3rd. Morgan Stanley decreased their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. Leerink Swann raised shares of Illumina to an “outperform” rating and decreased their price objective for the stock from $380.00 to $365.00 in a research report on Wednesday, January 30th. Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target on the stock. in a research note on Friday, January 25th. Finally, Bank of America reiterated a “buy” rating and set a $355.00 price target on shares of Illumina in a research note on Wednesday, January 30th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $345.82.
Shares of NASDAQ ILMN opened at $319.21 on Friday. Illumina, Inc. has a 12-month low of $225.82 and a 12-month high of $372.61. The stock has a market capitalization of $46.35 billion, a price-to-earnings ratio of 55.81, a price-to-earnings-growth ratio of 2.25 and a beta of 1.18. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the company earned $1.44 EPS. On average, equities analysts predict that Illumina, Inc. will post 6.53 EPS for the current fiscal year.
In related news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction that occurred on Wednesday, December 26th. The shares were sold at an average price of $273.87, for a total transaction of $903,771.00. Following the transaction, the director now owns 339,879 shares of the company’s stock, valued at $93,082,661.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Aimee L. Hoyt sold 298 shares of the company’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $304.63, for a total transaction of $90,779.74. Following the transaction, the senior vice president now directly owns 2,297 shares in the company, valued at approximately $699,735.11. The disclosure for this sale can be found here. Insiders have sold 35,526 shares of company stock worth $10,501,041 in the last three months. Insiders own 0.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Highlight Press and is owned by of Highlight Press. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://highlightpress.com/2019/03/22/illumina-inc-ilmn-stake-lessened-by-principal-financial-group-inc.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: What is the S&P 500 Index?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.